Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma

Sarcoma

This is a multicenter open-label, randomized, non-comparative, parallel cohort pivotal study of treatment with envafolimab (cohort A and C) or envafolimab combined with ipilimumab (cohort B and D) in patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) / myxofibrosarcoma (MFS) who have progressed on one or two lines of chemotherapy.
Sarcoma
II
Keedy, Vicki
NCT04480502
VICCSAR2076

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid / Round Cell Liposarcoma

Sarcoma

This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1 and Cohort 2) or MRCLS (Cohort 1) .
Sarcoma
II
Keedy, Vicki
NCT04044768
VICCSAR1948

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Multiple Cancer Types

TTX-080-01 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor) or cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies. The study is enrolling in the dose expansion cohorts.
Miscellaneous, Phase I
I
Keedy, Vicki
NCT04485013
VICCMD2172

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: